Pharmaceutical and biotech R&D is undergoing a notable shift in how therapeutic antibodies are discovered. Traditionally, antibody generation relied on immunizing animals (e.g. mice, rabbits, or even llamas) to raise binders against a target antigen. However, emerging synthetic antibody library technologies now allow scientists to bypass animal immunization by using in silico designed vast libraries of human or humanized antibody fragments. These synthetic libraries, especially those based on VHH single-domain antibodies (nanobodies), can yield high-affinity binders in a fraction of the time of animal-based methods and offer more control over key parameters such as affinity, specificity, and biophysical robustness.​

The Shift to Animal-Free Antibody Discovery

In April 2025, the FDA announced the phasing out of animal testing requirements for monoclonal antibodies and other drugs. While not yet a reality, in most cases, many preclinical studies still use established animal models—particularly to evaluate a drug’s toxicity, pharmacokinetics, late-stage toxicity, complex systemic effects and efficacy – before progressing to human trials. But if we look earlier in the antibody discovery process, there are earlier stages where opportunities to reduce animal use are already accessible and cost-effective. 

Phases such as target identification and validation, and predictive toxicology or pharmacokinetic modeling are increasingly being addressed  by advanced tools like artificial intelligence, in silico modeling, and organ-on-chip systems, enabling earlier decision-making and reducing reliance on animals for drug development.

Regulatory pressure and trends on animal models

The shift toward animal-free technologies aligns with mounting regulatory and ethical pressure to reduce animal use in drug discovery. Across the USA, Europe and globally, regulators are pushing for validated, non-animal methods wherever scientifically feasible.

Landmark FDA announcement

In the USA, the FDA Modernization Act 2.0 (2022) removed the requirement for animal testing in drug development, allowing validated non-animal methods to be used instead. In April 2025, the FDA announced a much larger shift in its regulatory approach: to phase out mandatory animal testing for mAbs drugs and certain IND applications. The agency now accepts validated non-animal methodologies—such as human organoids, AI-based models, and real-world human data—through a new pilot program and case-by-case exemptions. FDA Commissioner Marty Makary describes the move as a “paradigm shift” that aims to accelerate drug development while reducing reliance on animal models. Although full replacement may still take time, this decision reinforces a clear trend: non-animal methods are now recognised as viable regulatory alternatives —they’re becoming the regulatory standard. On the industry side, a 2021 AAPS commentary by major biopharma representatives recognized significant progress in reducing animal use—particularly through in vitro antibody libraries—and emphasized the need for increased data sharing to support the broader adoption of non-animal technologies. These developments point to a growing consensus: reducing long-term compliance risk  means moving away from animal reliance—sooner rather than later.

“It is a win-win for public health and ethics.” – FDA Commissioner Martin A. Makary, M.D., M.P.H.

European regulatory trends

In 2020, the EU’s Reference Laboratory for alternatives to animal testing (EURL ECVAM) explicitly recommended ending the use of animals for antibody development and production in research and therapeutics “where robust, legitimate scientific justification is lacking”​. 

A coalition of scientists echoed this, urging the European Commission to make non-animal-derived antibodies the default. While the League of European Research Universities (LERU) cautioned against a hasty ban, it supported gradual adoption to maintain competitiveness.

The EU’s regulatory stance is grounded in the 3Rs principle—Replacement, Reduction, and Refinement—enshrined in laws like Directive 2010/63/EU and REACH. Though uptake has been slow due to validation and regulatory inertia, agencies like the ECHA are promoting human-relevant, mechanistic models.

Worldwide regulatory trends

The UK’s NC3Rs reported that over one million animals are still used annually in the EU for antibody production, despite existing non-animal alternatives. In 2023, they brought together stakeholders to promote the adoption of Non-Animal Derived Antibodies (NADAs), emphasizing both ethical advantages and improvements in reproducibility and reagent quality.

These developments point to a growing consensus: reducing long-term compliance risk  means moving away from animal reliance—sooner rather than later.

It’s not the end, but a new beginning

For companies like Isogenica and others specializing in synthetic antibody libraries, these regulatory trends are highly encouraging. Synthetic VHH libraries are intrinsically aligned with the direction policymakers and industry leaders are heading. By adopting fully in vitro discovery pipelines, organizations can reduce the risk of future regulatory friction in their discovery workflows against tightening animal-use restrictions. Moreover, advanced  in vitro solutions mean they can do so while maintaining high standards of quality, meeting the required potency, specificity, and developability profiles for clinical development.

Moreover, larger synthetic platforms offer improved diversity, eliminating biological variability inherent to animal-based methods. This results in antibodies with fewer freedom to operate risks, and less engineering required to reduce immunogenicity or edit out manufacturing liabilities – all meaning faster and more efficient progression towards the preclinical stage.

These benefits are already being demonstrated in peer-reviewed studies and discovery programs and they are already being demonstrated across R&D programs globally. With regulatory expectations shifting, now is the time for forward-looking organizations to evaluate synthetic technologies not just as alternatives, but as a robust “new normal”.

Curious to see how Isogenica’s synthetic libraries perform? Download our Whitepaper – Data Driven Validation of Synthetic VHHs

This example reinforces the opportunity to improve efficiency while aligning with emerging ethical and regulatory standards.

Not hype, but regulatory and scientific momentum

Across Europe and North America, regulators are converging on a clear direction: reduce animal use in biomedical R&D wherever scientifically feasible. In the EU, the 3Rs ethical principle has become a legal standard supported by directives and official recommendations. The UK’s NC3Rs and the U.S. FDA have taken similar steps by promoting non-animal models and formally allowing them in regulatory testing pathways.

While not yet compulsory for antibody discovery, these developments signal a broader trend. Synthetic, human-relevant platforms such as VHH libraries are increasingly seen as viable tools to future-proof discovery programs and meet rising expectations in both science and policy. Companies with R&D departments—whether in pharmaceuticals, cosmetics, food, and many others—still have time to get on board to remain competitive and compliant.

Future perspectives and trends

Synthetic single-domain antibody libraries represent a powerful convergence of technology and ethics in therapeutic development. Isogenica’s Whitepaper illustrates how a thoughtfully designed VHH library can rapidly yield high-affinity leads entirely without animal immunization. You can read many other examples like this one in our Blog section.

These cases provide a compelling proof-of-concept that we can replace the old animal-dependent paradigms with modern, synthetic methods without compromising on results. In fact, by offering speed, control, scalability, and human-centric design, synthetic libraries often outperform traditional methods in meeting today’s drug discovery challenges. Crucially, this approach positions organizations to comply with and even get ahead of emerging regulations that favor the 3Rs. 

The shift toward animal-free antibody discovery is no longer speculative—it’s underway. Synthetic VHH libraries not only accelerate R&D and reduce ethical concerns but also position companies for long-term regulatory compliance and scientific leadership.

If you’re exploring how to integrate synthetic approaches into your discovery pipeline to advance discovery goals with improved reproducibility and control, speak with our scientific team about your next VHH discovery project.